Article

Development of the Cerebrospinal Fluid in Early Stage after Hemorrhage in the Central Nervous System

Petr Kelbich 1,2,3,*, Aleš Hejčl 4,5,6, Jan Krejsek 7, Tomáš Radovnický 4, Inka Matuchová 1,2,3, Jan Lodin 4, Jan Špička 7, Martin Sameš 4,8, Jan Procházka 9, Eva Hanuljaková 1,3 and Petr Vachata 4,10

Abstract: Extravasation of blood in the central nervous system (CNS) represents a very strong damaged associated molecular patterns (DAMP) which is followed by rapid inflammation and can participate in worse outcome of patients. We analyzed cerebrospinal fluid (CSF) from 139 patients after the CNS hemorrhage. We compared 109 survivors (Glasgow Outcome Score (GOS) 5-3) and 30 patients with poor outcomes (GOS 2-1). Statistical evaluations were performed using the Wilcoxon signed-rank test and the Mann–Whitney U test. Almost the same numbers of erythrocytes in both subgroups appeared in days 0–3 (p = 0.927) and a significant increase in patients with GOS 2-1 in days 7–10 after the hemorrhage (p = 0.004) revealed persistence of extravascular blood in the CNS as an adverse factor. We assess 43.3% of patients with GOS 2-1 and only 27.5% of patients with GOS 5-3 with low values of the coefficient of energy balance (KEB < 15.0) in days 0–3 as the evidence of immediate simultaneously manifested intensive inflammation, swelling of the brain and elevation of intracranial pressure.

Keywords: CNS haemorrhage; inflammation in CNS; cerebrospinal fluid; total protein in CSF; erythrocytes in CSF; neutrophils in CSF; coefficient of energy balance; aspartate aminotransferase in CSF

1. Introduction

Hemorrhage in the central nervous system (CNS) is associated with a high risk of severe impairment of CNS or even the death [1–3]. Despite survive in the initial period patients are at the risk of severe complications such as microvessel constriction, large...
vessel vasospasm, re-bleeding or bacterial neuroinfection [2–9]. These patients are monitored at intensive care units including clinical evaluation, repeated computed tomography scans, invasive intracranial monitoring as well as repeated cerebrospinal fluid (CSF) analysis [10–12].

Hemorrhage in the CNS induces a local inflammatory response. Dumont et al. refer inflammation in response to subarachnoid blood as a plausible candidate pathway leading to cerebral vasospasm [2]. Wang reviews the roles of cytokines, proteases, and reactive oxygen species (ROS) in the intracranial hemorrhage (ICH) induced secondary brain injury. The special role in its pathogenesis is given to neutrophils [3]. Fassbender et al. found that the release of IL-1β, IL-6 and TNFα in the subarachnoidal space of patients with SAH is associated with the development of increased cerebral blood flow velocities in basal cerebral arteries. They observed that intrathecal secretion of proinflammatory cytokines after SAH is significantly increased in patients with poor clinical outcome [4]. Sercombe et al. refer that if the SAH is not immediately fatal, it may be the subject to the next complications, in particular hypertension and, later, cerebral vasospasms and re-bleeding. They also describe the contribution of the inflammatory reaction in the subarachnoid compartment to the development of vasospasms [5]. Tso and Macdonald refer that after SAH inflammatory mediators such as interleukin (IL)-1β, IL-6 and tumor necrosis factor α (TNFα), and oxidative damage from neutrophils and macrophages may result in direct damage to the microvasculature, resulting in damage to the blood–brain barrier (BBB), brain edema and brain injury [7]. Miller et al. describe the relationship between elevations of inflammatory mediators in the CSF, onset of vasospasm and decreased neurological outcomes of patients after SAH. They found that TNFα levels in poor-grade SAH patients were shown to be correlated with severity of vasospasm. They consider further the CSF concentrations of IL-6 as an early marker to predict vasospasm development [8]. In addition, hemolytic events after CNS hemorrhage result in large quantities of extracellular hemoglobin. Subsequently, as the heme-iron of hemoglobin is converted from ferrous to ferric form, hemoglobin is oxidized quickly releasing its heme moieties. Extracellular hemoglobin/heme/iron initiates a cascade of free radical-induced damage, oxidative stress and formation of damage associated molecular patterns (DAMP) is initiating the inflammatory response. The complexes hemoglobin–haptoglobin are formed. These complexes are recognized by CD163 scavenger receptors expressed especially on alternatively polarized M2 macrophages. Complexes are internalized and intracellularly subjected to the action of hemoxigenase to eliminate their proinflammatory and oxidative potentials [13].

Our previous effort was to detect predominantly purulent inflammatory complications of bacterial origin in the CNS after hemorrhage using basic analysis of the CSF [6]. This retrospective study is aimed at the comprehensive assessment of local inflammation in the CSF in the early stage after the CNS hemorrhage and its relationship to the clinical outcome. We compared results of the CSF analysis of survivors (Glasgow Outcome Score [GOS] 5–3) and patients with poor outcome (GOS 2-1) on days 0–3 and 7–10 after the attack of hemorrhage.

### 1.1. Cytological Investigation of the CSF

The typical presentation of hemorrhage occurring within the CSF are erythrocytes with freshly phagocytosed or decolored erythrocytes, siderophages and hematoidin crystals [14–19].

The presence and composition of immunocompetent cells in the CSF was evaluated in our study. The presence of lymphocytes and monocytes is usually indicating slight serous inflammation which is typical for the posthemorrhagic clean-up reaction. The predominant presence of innate immunity cells, such as neutrophils, is indicating the inflammatory reaction to adverse consequences of hemorrhage within the CNS, especially vasospasms, re-bleeding and bacterial neuroinvasion [2,3,5,14–20].
1.2. Investigation of Biochemical Parameters in the CSF

We used parameters of basic biochemical analysis of the CSF. These are concentrations of total protein, energy parameters and a measurement of catalytic activities of aspartate aminotransferase (AST) in the CSF [18–23]. Their advantages are common availability, reliable analysis and immediate response at low price.

Concentration of the total protein in the CSF usually correlates with permeability of the blood-cerebrospinal fluid barrier. Nevertheless, high concentrations of the total protein in the CSF of patients after the CNS hemorrhage is very often influenced by impairment of the CSF circulation [18,24].

The AST catalytic activity in the CSF is reliable and easily accessible parameter of the CNS tissue injury [22].

Energy Assessment of Inflammation in the CSF

To address the presence and the extent of the immune reactions within the CSF compartment, it is essential to analyze functional as well as morphological parameters within the CSF. Activated immunocompetent cells display high energy requirements [25–28]. In order to evaluate the extent of immune system activation within the CSF compartment, measurement of energy parameters is performed. Many authors use molar concentrations of glucose or lactate in the CSF [9,29–36]. However, value of these parameters is limited. Concentrations of glucose in the CSF are dependent on the concentrations of blood glucose. Concentrations of lactate in the CSF are not only reflecting the extent of anaerobic metabolism in the CSF, but are also dependent on the supply of energy substrate (glucose). Therefore we derived an equation to identify the theoretical average number of molecules of adenosine triphosphate (ATP) produced from one molecule of glucose under set conditions in the CSF compartment. We call this parameter the coefficient of energy balance (KEB; in Czech Koefficient Energetické Bilance) [21,22,37]:

\[
\text{KEB} = 38 - 18 \frac{[\text{lactate}]}{[\text{glucose}]} \quad (1)
\]

Legend:

\([\text{glucose}] = \text{molar concentration of glucose in the CSF (mMol·L}^{-1})\).

\([\text{lactate}] = \text{molar concentration of lactate in the CSF (mMol·L}^{-1})\).

Normal energy condition in the CSF compartment is characterized with the high KEB values over 28.0. Activation of immunocompetent cells caused an increase of anaerobic metabolism which is presented by the decrease of KEB values under 28.0. The lowest KEB values (KEB < 10.0) are typical for very intensive inflammation with oxidative burst of professional phagocytes (neutrophils and macrophages) and ROS production—e.g., in the case of purulent inflammation [22,37].

2. Material and Methods

2.1. Patients

We selected 139 patients with two analyses of their CSF in this retrospective study. The first analysis was done in between the 0 to 3 day and the second one in between the 7th to 10th day after the CNS hemorrhage. On days 0–3 the perioperative collections of the CSF were completed with the purpose of cranial decompression, improvement of surgical conditions and gaining of input information about the CSF compartment. All takings were made using lumbar puncture or drainage.

The patients were clinically evaluated during hospital discharge using the Glasgow Outcome Score (GOS). We divided these patients into two subgroups—109 survivors (GOS 5-3) and 30 patients with poor outcome (GOS 2-1) (Table 1).
Table 1. Distribution of our patients in accordance with outcome, the type of the CNS hemorrhage and demographic data.

| Groups of Patients | GOS 5-3 | GOS 2-1 |
|-------------------|---------|---------|
| Sex               | Females | Males   | Females | Males   |
| number            | 66      | 43      | 12      | 18      |
| median of age     | 61      | 60      | 73      | 64      |
| minimal age       | 25      | 33      | 44      | 44      |
| maximal age       | 88      | 84      | 83      | 77      |
| SAH               | 52      | 25      | 8       | 7       |
| ICH               | 10      | 18      | 3       | 9       |
| SAH + ICH         | 4       | 0       | 1       | 2       |

Legend: GOS—Glasgow Outcome Score; SAH—number of causes with subarachnoid hemorrhage; ICH—number of causes with intracerebral hemorrhage.

Furthermore, we present CSF findings in two considerably different control groups of patients—500 patients with normal CSF findings and 109 patients with purulent inflammation in the CNS.

2.2. CSF Analysis

CSF samples were repetitively obtained via external CSF drainage into a test tube without anticoagulation agents and immediately transported for laboratory examination. Immediately after receiving the sample, we evaluated the cell count and permanent cytological smear developed using a cyto-centrifuge method was made. Another part of the sample was centrifuged (10 min; 1500 \( \times g \)) and the concentrations of total protein, glucose, lactate and AST catalytic activities were determined. The rest of the supernatant was temporarily stored in refrigerator at +4 °C to +8 °C for potential future analysis.

In each case, we calculated the total number of elements in the CSF using a Fuchs-Rosenthal chamber and evaluated smear stained with Hemacolor (Merck Co., Darmstadt, Germany). Olympus BX40 microscope (Olympus, Tokio, Japan) was used.

We analyzed molar concentrations of glucose in the CSF using the hexokinase method, molar concentrations of lactate in the CSF using the lactate–oxidase and peroxidase, mass concentrations of total protein in the CSF using the turbidimetric method with benzetonium chloride and catalytic activities of AST in the CSF using the IFCC (International Federation of Clinical Chemistry) method with a Cobas 6000 analyzer (Roche Co., Basel, Switzerland). We calculated the KEB for each case [22,37].

2.3. Statistical Analysis

Concentrations of total protein, glucose and lactate, KEB values, numbers of nucleated cells and erythrocytes, the percentage of neutrophils and AST catalytic activities in the CSF are presented in Tables 2 and 3 as a median and the 1st and the 3rd quartile. Firstly, we tested differences between these parameters on days 0–3 and 7–10 after the CNS hemorrhage in both subgroups of patients using the Wilcoxon signed-rank test (Table 2). Secondly, we tested differences between these parameters in both subgroups of patients on days 0–3 and 7–10 after the CNS hemorrhage using the Mann–Whitney U test (Table 3). All statistical tests were done via Statistica 13.3 software (StatSoft Inc., Tulsa, OK, USA) and \( p \) values < 0.05 were considered as significant.
Table 2. Investigation of the CSF of patients after the CNS hemorrhage—comparison between days 0 and 3 and 7 and 10 after the CNS hemorrhage; and two control groups of patients with normal findings and with purulent inflammation in the CNS.

| CSF Parameters | Normal Findings | Purulent Inflammation in the Central Nervous System (CNS) | GOS 5–3 | GOS 2–1 |
|----------------|-----------------|----------------------------------------------------------|---------|---------|
| Erythrocytes | 0 (0–1) | 160 (21–843) |  |  |
| (elements/1 µL) |  | |  |  |
| Leukocytes | 1 (1–2) | 2513 (800–6783) |  |  |
| (elements/1 µL) |  | |  |  |
| Neutrophils (%) | 0 (0–0) | 83 (73–90) |  |  |
| Total protein (mg/L) | 296.0 (243.75–354.0) | 3021.5 (1596.75–5416.0) | 1625.0 (590.0–3990.0) | 1875.5 (384.75–1838.25) |
| Glucose (mmol/L) | 3.41 (3.19–3.65) | 0.50 (0.03–1.80) | 4.60 (3.84–5.70) | 4.24 (3.43–5.41) |
| Lactate (mmol/L) | 1.49 (1.35–1.60) | 10.43 (6.77–13.36) | 5.55 (3.29–6.15) | 4.23 (3.23–5.74) |
| KEB | 30.23 (29.55–30.94) | −369.88 (−6184 to −36.98) |  |  |
| AST (IU/L) | 12.6 (10.2–15.0) | 21.6 (16.8–46.2) | 12.0 (6.6–24.0) | 31.8 (24.0–63.0) |

Legend: GOS: Glasgow Outcome Score; n: number of patients; KEB: coefficient of energy balance; AST: aspartate aminotransferase; *: statistically significant (p < 0.05)—tested using by the Wilcoxon signed−rank test.
Table 3. Investigation of the cerebrospinal fluid (CSF) in two subgroups of patients after the CNS hemorrhage.

| CSF Parameters | GOS 5-3 n = 109 | GOS 2-1 n = 30 | GOS 5-3 n = 109 | GOS 2-1 n = 30 |
|----------------|-----------------|----------------|-----------------|----------------|
| **Erythrocytes** (elements/1 µL) |                  |                |                 |                |
|                | p = 0.927       | p = 0.004 *    |                 |                |
| Day 0–3        | 26,112 (7680–98,133) | 24,747 (6272–165,973) | 13,867 (2475–48,640) | 40,875 (12,885–144,768) |
| Day 7–10       | 24,747 (6272–165,973) | 13,867 (2475–48,640) | 40,875 (12,885–144,768) |                |
| **Leukocytes** (elements/1 µL) |                  |                |                 |                |
|                | p = 0.312       | p = 0.747      |                |                |
| Day 0–3        | 47 (12–381)     | 41 (5–193)     | 141 (37–523)   | 209 (60–700)   |
| Day 7–10       | 41 (5–193)      | 141 (37–523)   | 209 (60–700)   |                |
| **Neutrophils** (%) |              |                |                 |                |
|                | p = 0.547       | p = 0.947      |                |                |
| Day 0–3        | 46 (26–66)      | 50 (27–76)     | 54 (36–67)     | 47 (36–69)     |
| Day 7–10       | 50 (27–76)      | 54 (36–67)     | 47 (36–69)     |                |
| **Total protein** (mg/L) |                  |                |                 |                |
|                | p = 0.008 *     | p = 0.126      |                |                |
| Day 0–3        | 1625.0 (590.0–3990.0) | 4049.5 (1308.25–10,775.0) | 654.0 (378.0–1047.0) | 887.5 (384.75–1838.25) |
| Day 7–10       | 4049.5 (1308.25–10,775.0) | 654.0 (378.0–1047.0) | 887.5 (384.75–1838.25) |                |
| **Glucose** (mmol/L) |                  |                |                 |                |
|                | p = 0.003 *     | p = 0.048 *    |                |                |
| Day 0–3        | 4.60 (3.84–5.70) | 5.77 (4.87–6.89) | 3.54 (2.80–4.58) | 4.24 (3.43–5.41) |
| Day 7–10       | 5.77 (4.87–6.89) | 3.54 (2.80–4.58) | 4.24 (3.43–5.41) |                |
| **Lactate** (mmol/L) |                  |                |                 |                |
|                | p < 0.001 *     | p = 0.097      |                |                |
| Day 0–3        | 4.55 (3.29–6.15) | 6.84 (4.60–8.72) | 3.62 (2.87–5.23) | 4.23 (3.23–5.74) |
| Day 7–10       | 6.84 (4.60–8.72) | 3.62 (2.87–5.23) | 4.23 (3.23–5.74) |                |
| **KEB** |                  |                |                 |                |
|                | p = 0.317       | p = 0.937      |                |                |
| Day 0–3        | 21.16 (12.43–26.60) | 17.48 (6.87–25.07) | 20.79 (5.82–27.30) | 20.67 (10.41–25.08) |
| Day 7–10       | 17.48 (6.87–25.07) | 20.79 (5.82–27.30) | 20.67 (10.41–25.08) |                |
| **AST** (IU/L) |                  |                |                 |                |
|                | p = 0.242       | p = 0.047 *    |                |                |
| Day 0–3        | 12.0 (6.6–24.0)  | 16.8 (9.6–25.2) | 24.6 (13.8–37.2) | 31.8 (24.0–63.0) |
| Day 7–10       | 16.8 (9.6–25.2)  | 24.6 (13.8–37.2) | 31.8 (24.0–63.0) |                |

Legend: GOS: Glasgow Outcome Score; n: number of patients; KEB: coefficient of energy balance; AST: aspartate aminotransferase; *: statistically significant ($p < 0.05$)—tested using the Mann-Whitney U test.

3. Results

Tables 2 and 3 present the comparisons between CSF parameters of survivors (GOS 5-3) and patients with poor outcome (GOS 2-1) immediately (days 0–3) and later (days 7–10) after the CNS hemorrhage. In addition, the Table 2 contents data of two control subgroups of patients—with normal CSF findings and with purulent inflammation in the CNS (Table 2).

Immediately after the CNS hemorrhage the numbers of erythrocytes in the CSF were almost the same in survivors and patients with poor outcome. Significant differences between these subgroups were apparent in days 7–10. While number of erythrocytes in the CSF of survivors significantly decreased, their number in patients with poor outcome was insignificantly higher (Tables 2 and 3).

The increase in the number of leukocytes in the CSF on days 0–3 and on days 7–10 after the CNS hemorrhage in both subgroups of patients was approximately the same. It is significant in survivors and insignificant in patients with poor outcome (Tables 2 and 3).

Relative count of neutrophils in the CSF of both subgroups of patients on days 0–3 and 7–10 after the CNS hemorrhage were approximately the same (Tables 2 and 3).

The elevation of total protein in the CSF immediately after the CNS hemorrhage was significantly higher in patients with poor outcome compared to survivors. On days 7–10 their values were approximately the same. The decrease of concentrations of total protein in the CSF during this time was significant in both subgroups of patients (Tables 2 and 3).
Significantly higher concentrations of glucose in the CSF were found in patients with poor outcome compared to survivors on days 0–3 and 7–10 after the CNS hemorrhage. They significantly decreased in time in both subgroups of our patients (Tables 2 and 3).

Immediately after the CNS hemorrhage the concentrations of lactate in the CSF were significantly higher in patients with poor outcome compared to survivors. They significantly decreased over time to similar values on days 7–10 after the CNS hemorrhage (Tables 2 and 3).

Decreased KEB values in the CSF presented the higher extent of anaerobic metabolism in the CSF compartment in survivors and patients with poor outcome. They were neither significantly different in both subgroups of patients nor in time after the CNS hemorrhage (Tables 2 and 3).

Immediately after the CNS hemorrhage AST catalytic activities in the CSF were similar in survivors and patients with poor outcome. Their significant increase was apparent in both subgroups between the days 0 and 3 and the days 7 and 10 after the CNS hemorrhage. The growth of AST catalytic activities was higher in patients with poor outcome (Tables 2 and 3).

We found apparently more causes with low KEB values (<15.0) and apparently less causes with moderate KEB values (15.0–28.0) in patients with poor outcome compared with survivors immediately after the CNS hemorrhage (Figure 1).

![Figure 1](image1.png)

**Figure 1.** Frequencies of patients divided in accordance with KEB values in 0–3 days after the CNS hemorrhage.

The differences between frequencies of patients of both subgroups divided in accordance with their KEB values were not significant on days 7–10 after the hemorrhage (Figure 2).

![Figure 2](image2.png)

**Figure 2.** Frequencies of patients divided in accordance with KEB values in 7–10 days after the CNS hemorrhage.
While frequencies of survivors and patients with poor outcome with AST catalytic activities more than 30.0 IU/L in the CSF immediately after the CNS hemorrhage were almost the same, on days 7–10 frequency of patients with poor outcome was significantly higher (Figure 3).

Figure 3. Frequencies of patients with AST catalytic activities >30.0 IU/L in the CSF in days 0–3 and 7–10 after the CNS hemorrhage.

4. Discussion

The CNS hemorrhage is a very serious brain injury with a high risk of persistent neurology deficits or even the death. Many variables can influence the outcome of patients. We focused on the CSF monitoring of these patients over several days and divided them into two subgroups in accordance with the severity of their impairment—survivors (GOS 5-3) and patients with poor outcomes (GOS 2-1). All these patients were followed during the first 3 days and on the second occasion between the 7th to 10th day after the CNS hemorrhage.

Some authors recognize the amount of bleeding in the CNS as one of the important factors of its prognosis [3,7]. In the contrary to this finding, we found similar numbers of erythrocytes in the CSF of both subgroups of our patients during the first three days after the CNS hemorrhage (Table 2). Significant differences between survivors and patients with poor outcome were only found in days 7 to 10 (Table 3). Whereas the count of erythrocytes significantly decreased in survivors, in patients with a poor outcome, numbers of erythrocytes did not decline. We concluded that this was due to a persistence of bleeding, a gradual release of large amounts of extravascular erythrocytes from the CNS into the CSF or re-bleeding in patients with a poor outcome [5]. On the other hand, relatively small amounts of extravascularly localized erythrocytes in the CNS of survivors were eliminated by the clean-up reaction effectively [15–19].

CNS hemorrhage and its consequent complications are evoking damaging local inflammatory response in the CNS [2–9]. Increased numbers of leukocytes, higher relative number of neutrophils and decreased KEB values in the CSF of survivors and patients with poor outcome are the evidences of local inflammatory response in the CNS after a hemorrhage in both subgroups of patients (Tables 2 and 3) [3,21,22,37]. We compared the extent of inflammation in the CSF compartment between these subgroups using the cytological-energy investigation of the CSF. Immediately after the CNS hemorrhage the numbers of leukocytes in the CSF did not differ when compare both groups of patients (Table 3). Their next elevation in days 7 to 10 was also very similar in all patients (Table 1). In addition, we did not find any differences in the relative number of neutrophils in the CSF in both subgroups (Tables 2 and 3). Therefore, it is not possible to consider the presence of immunocompetent cells in the CSF after the CNS hemorrhage as a suitable biomarker to predict the clinical outcome of patients.

Slightly decreased KEB values in patients with GOS 2-1 compared to patients with GOS 5-3 immediately after the CNS hemorrhage represents a trend to higher intensity of
inflammation in patients with poor outcome. In addition, we found 43.3% of patients with poor outcome and only 27.5% survivors with very low KEB values under 15.0 (Figure 1). Anaerobic metabolism in the CSF compartment with KEB values under 15.0 usually reflects very intensive inflammatory complications with oxidative burst of professional phagocytes [22,37].

Elevation of total protein in the CSF immediately after the CNS hemorrhage is simultaneously influenced by many variables—amount of extravascular blood, inflammatory response and disorder of the CSF circulation to name some of them. It seems that the inflammatory reaction in the CNS immediately after the hemorrhage plays the key role. Inflammation is accompanied by a higher increase in the permeability of the blood-brain barrier (BBB) and presence of proinflammatory mediators in the CNS. It results in swelling of the brain, increase of intracranial pressure (ICP) and impairment of blood circulation in the brain and circulation of the CSF. In addition, inflammation in the CNS increases risk of vasospasms and secondary cerebral ischemia [2-5,7,8,24].

Elevation of total protein in the CSF is found in both subgroups of our patients. It is significantly higher in patients with poor outcome (Table 3). The concentrations of total protein in the CSF decline fast on the similar values in both subgroups during the first week after the CNS hemorrhage (Tables 2 and 3). We conclude that the high concentration of total protein in the CSF of patients with poor outcome immediately after the CNS hemorrhage, together with a high amount of extravascular blood, represent the trend to intensive inflammatory reaction, swelling of the brain tissues and disorder of the CSF circulation.

Concentrations of glucose in the CSF of patients with poor outcomes compared with survivors were significantly higher in days 0 to 3 after the CNS hemorrhage (Table 3). Significant decline of glucose concentrations in the CSF in both subgroups of our patients was observed in days 7 to 10 (Table 2) probably reflecting the systemic changes in glucose metabolism. Our findings are in accord with the study of Matthew et al. who found hyperglycemia as a significant factor of poor outcome after aneurysmal SAH [38]. Similar dynamic of lactate concentrations in the CSF of our patients reflects the changes of glucose concentrations in relatively stabilized energy conditions in the CSF compartment (Tables 2 and 3) [39,40].

AST catalytic activity in the CSF is recognized as a useful parameter to detect CNS tissue injury. However, its values in survivors and patients with poor outcome were not significantly different immediately after the CNS hemorrhage (Table 2). Only a few days later their elevation in the CSF of patients with poor outcomes was higher compared with survivors and represented significant progression of irreversible damage of the CNS tissue of these patients (Table 2 and Figure 3). These results are not surprising, because they are in accord with the conclusions of our recent study [23].

5. Conclusions

Extravasation of blood in the CNS parenchyma represents a very strong DAMP (damaged associated molecular patterns) which is followed by rapid inflammatory response and other pathologies which can cause worse outcome of patients.

The battery of our tests to monitor the CSF in patients after a CNS hemorrhage comprises the absolute count of leukocytes and erythrocytes, the differential cell count, concentrations of total protein, glucose and lactate, the calculation of the KEB values and catalytic activities of AST. We compared these parameters in two subgroups of patients after a CNS hemorrhage—in survivors (GOS 5-3) and in patients with poor outcome (GOS 2-1).

We found two key adverse prognostic factors. The first one is the persistence of bleeding or re-bleeding in the CNS. The second ones are the low KEB values (<15.0) and increased total protein concentration in the CSF both representing trend to the very intensive early inflammatory response in the CNS, brain swelling, elevation of intracranial pressure and impairment of the CSF circulation. Subsequently increased AST catalytic
activities in the CSF of patients with poor outcome reveal more profound structural tissue injury in their CNS.

**Author Contributions:** Conceptualization, P.K., A.H., J.K. and P.V.; methodology, P.K.; software, I.M.; validation, P.K., J.S. and E.H.; formal analysis, I.M.; investigation, P.K., A.H., T.R., J.L., M.S., J.P. and E.H.; resources, P.K., A.H., T.R., J.L., J.S., M.S. and J.P.; data curation, P.K.; writing—original draft preparation, P.K. and J.L.; writing—review and editing, A.H., J.K. and P.V.; visualization, P.K.; supervision, M.S. and P.V.; project administration, P.K.; funding acquisition, P.V. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by The Internal Grants of the Krajská zdravotní, a.s. in Ústí nad Labem, Czech Republic “IGA-KZ-2019-1-7” and “IGA-KZ-2020-1-7” and by project “PROGRES Q40/10’ of Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the local Ethics Committee of the Masaryk Hospital in Ústí nad Labem (protocol code 289/17 and date of approval 25 November 2021).

**Informed Consent Statement:** Not applicable. The work did not involve any human experiments and did not require the collection of data out of common routine investigation. All patient records and information were anonymized and deidentified.

**Data Availability Statement:** All relevant data are within the paper.

**Acknowledgments:** We thank Květoslava Šýkorová for preparation of patient database and Gregory Jeffrey Evans for critical proofreading of the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Sreekrishnan, A.; Dearborn, J.L.; Greer, D.M.; Shi, F.-D.; Hwang, D.Y.; Leasure, A.C.; Zhou, S.E.; Gilmore, E.J.; Matouk, C.C.; Petersen, N.H.; et al. Intracerebral hemorrhage location and functional outcomes of patients: A systematic literature review and meta-analysis. *Neurocrit. Care* 2016, 25, 384–391. [CrossRef]

2. Dumont, A.S.; Dumont, R.J.; Chow, M.M.; Lin, C.; Calisaneller, T.; Ley, K.F.; Kassell, N.F.; Lee, K.S. Cerebral vasospasm after subarachnoid hemorrhage: Putative role of inflammation. *Neurosurgery* 2003, 53, 123–135. [CrossRef] [PubMed]

3. Wang, J. Preclinical and clinical research on inflammation after intracerebral hemorrhage. *Progress Neurobiol.* 2010, 92, 463–477. [CrossRef]

4. Fassbender, K.; Hodapp, B.; Rossol, S.; Bertsch, T.; Schmeck, J.; Schütt, S.; Fritzinger, M.; Horn, P.; Vajkoczy, P.; Kreisel, S.; et al. Inflammatory cytokines in subarachnoid haemorrhage: Association with abnormal blood flow velocities in basal cerebral arteries. *J. Neurol. Neurosurg. Psychiatry* 2001, 70, 534–537. [CrossRef] [PubMed]

5. Sercombe, R.; Dinh, Y.R.T.; Gomis, P. Cerebrovascular inflammation following subarachnoid hemorrhage. *Jpn. J. Pharmacol.* 2002, 88, 227–249. [CrossRef] [PubMed]

6. Beer, R.; Pfäusler, B.; Schmutzhard, E. Infectious intracranial complications in the neuro-ICU patient population. *Curr. Opin. Crit. Care* 2010, 16, 117–122. [CrossRef] [PubMed]

7. Tso, M.K.; Macdonald, R.L. Acute microvascular changes after subarachnoid hemorrhage and transient global cerebral ischemia. *Stroke Res. Treat.* 2013, 2013, 425281. [CrossRef] [PubMed]

8. Miller, B.A.; Turan, N.; Chau, M.; Pradilla, G. Inflammation, Vasospasm, and brain injury after subarachnoid hemorrhage. *Biomed. Res. Ind.* 2014, 2014, 384342. [CrossRef]

9. Hoogmoed, J.; van de Beek, D.; Coert, B.A.; Horn, J.; Vandertop, W.P.; Verbaan, D. Clinical and laboratory characteristics for the diagnosis of bacterial ventriculitis after aneurysmal subarachnoid hemorrhage. *Neurocrit. Care* 2017, 26, 326–370. [CrossRef]

10. Winn, H.R. Youmans Neurological Surgery 4-Volume Set, 6th ed.; ElsevierSaunders: Amsterdam, The Netherlands, 2011.

11. Hejčl, A.; Bolcha, M.; Procházková, J.; Hušková, E.; Sameš, M. Elevated intracranial pressure, low cerebral perfusion pressure, and impaired brain metabolism correlate with fatal outcome after severe brain injury. *J. Neurol. Surg. A Cent. Eur. Neurosurg.* 2012, 73, 10–17. [CrossRef]

12. Hejčl, A.; Cihlář, F.; Smolka, V.; Vachata, P.; Bartoš, R.; Procházková, J.; Cihlář, J.; Sameš, M. Chemical angioplasty with spasmodlytics for vasospasm after subarachnoid hemorrhage. *Acta Neurochir.* 2017, 159, 713–720. [CrossRef]

13. Leclerc, J.L.; Lampert, A.S.; Amador, C.L.; Schlakman, B.; Vasilopoulos, T.; Svendsen, P.; Moestrup, S.K.; Doré, S. The absence of the CD163 receptor has distinct temporal influences on intracerebral hemorrhage outcomes. *J. Cereb. Blood Flow Metab.* 2017, 38, 262–273. [CrossRef]
14. Deisenhammer, F.; Bartos, A.; Egg, R.; Gilhousen, N.E.; Giovannoni, G.; Rauer, S.; Sellebjerg, F. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. *Eur. J. Neurol.* 2006, 13, 913–922. [CrossRef]

15. Gulati, R.; Menon, M.P. Indicators of true intracerebral hemorrhage: Hematoidin, siderophagia, and erythrophagia. *Blood* 2015, 125, 3664. [CrossRef] [PubMed]

16. Nagy, K.; Skagervik, I.; Tumani, H.; Petzold, A.; Wick, M.; Kühn, H.-J.; Uhr, M.; Regeniter, A.; Brettschneider, J.; Otto, M.; et al. Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage? *Clin. Chem. Lab. Med.* 2014, 51, 2073–2086.

17. Torzewski, M.; Lackner, K.J. Cerebrospinal fluid cytology: A highly diagnostic method for the detection of diseases of the central nervous system. *J. Lab. Med.* 2016, 40, 191–198. [CrossRef]

18. Adam, P.; Táborský, L.; Sobek, O.; Hildebrand, T.; Kelbich, P.; Prucha, M.; Hyánek, J. Cerebrospinal fluid. In *Advances in Clinical Chemistry*, 1st ed.; Academic Press: San Diego, CA, USA, 2001; pp. 1–62.

19. Schwenkenbecher, P.; Janssen, T.; Wurster, U.; Konen, F.F.; Neyazi, A.; Ahlbrecht, J.; Puppe, W.; Bönig, L.; Sühs, K.-W.; Stangel, M.; et al. The influence of blood contamination on cerebrospinal fluid diagnostics. *Front. Neurol.* 2019, 10, 584. [CrossRef]

20. Provencio, J.J.; Fu, X.; Siu, A.; Rasmussen, P.A.; Hazen, S.L.; Ransohoff, R.M. CSF neutrophils are implicated in the development of vasospasm in subarachnoid hemorrhage. *Neurocrit. Care* 2010, 12, 244–251. [CrossRef]

21. Kelbich, P.; Slavík, J.; Jasanská, J.; Adam, P.; Hanuljaková, E.; Jermanová, K.; Repková, E.; Šimečková, M.; Procházková, J.; Gajdošová, R.; et al. Evaluations of the energy relations in the CSF compartment by the determination of selected parameters of the glucose metabolism in the CSF. *Klin. Biochem. Metab.* 1998, 6, 213–225.

22. Kelbich, P.; Hejčl, A.; Selke Krulichová, J.; Procházková, J.; Hanuljaková, E.; Peruthová, J.; Koudelková, M.; Sameš, M.; Krejsek, J. Coefficient of energy balance, a new parameter for basic investigation of the cerebrospinal fluid. *Clin. Chem. Lab. Med.* 2014, 52, 1009–1017. [CrossRef]

23. Kelbich, P.; Radovník, T.; Selke-Kruščíková, I.; Lodin, J.; Matuchová, I.; Sameš, M.; Procházková, J.; Krejsek, J.; Hanuljaková, E.; Hejčl, A. Can aspartate aminotransferase in the cerebrospinal fluid be a reliable predictive parameter? *Brain Sci.* 2020, 10, 698. [CrossRef]

24. Reiber, H. Dynamics of brain-derived proteins in cerebrospinal fluid. *Clin. Chim. Acta* 2001, 310, 173–186. [CrossRef]

25. O’Neill, L.A.J.; Kishton, R.J.; Rathmell, J. A guide to immunometabolism for immunologists. *Nat. Rev. Immunol.* 2016, 16, 553–565. [CrossRef] [PubMed]

26. Loftus, R.M.; Finlay, D.K. Immunometabolism: Cellular metabolism turns immune regulator. *J. Biol. Chem.* 2016, 291, 1–10. [CrossRef] [PubMed]

27. Wei, J.; Raynor, J.; Nguyen, M.H.; Chi, H. Nutrient and metabolic sensing in T cell responses. *Front. Immunol.* 2017, 8, 247. [CrossRef] [PubMed]

28. Borregaard, N.; Herlin, T. Energy metabolism of human neutrophils during phagocytosis. *J. Clin. Invest.* 1982, 70, 550–557. [CrossRef]

29. Huy, N.T.; Thao, N.T.H.; Diep, D.T.N.; Kikuchi, M.; Zamora, J.; Hirayama, K. Cerebrospinal fluid lactate concentration to distinguish bacterial from aseptic meningitis: A systemic review and meta-analysis. *Crit. Care* 2010, 14, R240. [CrossRef] [PubMed]

30. Prasad, K.; Sahu, J.K. Cerebrospinal fluid lactate level. Is it a reliable and valid marker to distinguish between acute bacterial meningitis and aseptic meningitis? *Crit. Care* 2011, 15, 104.

31. Viallon, A.; Desseigne, N.; Marjollet, O.; Birynczyk, A.; Belin, M.; Guyomarch, S.; Borg, J.; Pozzetto, B.; Bertrand, J.C.; Zeni, F. Meningitis in adult patients with a negative direct cerebrospinal fluid examination: Value of cytochemical markers for differential diagnosis. *Crit. Care* 2011, 15, R136. [CrossRef] [PubMed]

32. Leen, W.G.; Willemsen, M.A.; Wevers, R.A.; Verbeek, M.M. Cerebrospinal fluid glucose and lactate: Age-specific reference values and implications for clinical practice. *PLoS ONE* 2012, 7, e42745. [CrossRef]

33. Hegen, H.; Auer, M.; Deisenhammer, F. Serum glucose adjusted cut-off values for normal cerebrospinal fluid/serum glucose ratio: Implications for clinical practice. *Clin. Chem. Lab. Med.* 2014, 52, 1335–1340. [CrossRef] [PubMed]

34. Filho, E.M.; Horita, S.M.; Gilio, A.E.; Gigovic, L.E. Cerebrospinal fluid lactate level as a diagnostic biomarker for bacterial meningitis in children. *Int. J. Emerg. Med.* 2014, 7, 14. [CrossRef] [PubMed]

35. Li, Y.; Zhang, G.; Ma, R.; Du, Y.; Zhang, L.; Li, F.; Fang, F.; Lv, H.; Wang, Q.; Zhang, Y.; et al. The diagnostic value of cerebrospinal fluids procalcitonin and lactate for the differential diagnosis of post-neurosurgical bacterial meningitis and aseptic meningitis. *Clin. Biochem.* 2015, 48, 50–54. [CrossRef]

36. Slack, S.D.; Turley, P.; Allgar, V.; Holbrook, I.B. Cerebrospinal fluid lactate: Measurement of an adult reference interval. *Ann. Clin. Biochem.* 2016, 53, 164–167. [CrossRef]

37. Kelbich, P.; Hejčl, A.; Staněk, I.; Svitilová, E.; Hanuljaková, E.; Sameš, M. Principles of the cytological-energy analysis of the extravascular body fluids. *Biochem. Mol. Biol. J.* 2017, 3, 6. [CrossRef]

38. McGirt, M.J.; Woodworth, G.F.; Ali, M.; Than, K.D.; Tamargo, R.J.; Clatterbuck, R.E. Persistent perioperative hyperglycemia as an independent predictor of poor outcome after aneurismal subarachnoid hemorrhage. *J. Neurosurg.* 2007, 107, 1080–1085. [CrossRef]

39. Karlson, P. *Kurzes Lehrbuch der Biochemie für Mediziner und Naturwissenschaftler*, 10th ed.; Georg Thieme Verlag: Stuttgart, Germany, 1977.

40. Murray, R.K.; Granner, D.K.; Mayes, P.A.; Rodwell, V.W. *Harper’s Biochemistry*, 23th ed.; H&H: Prague, Czech Republic, 1998.